Genfit (GNFT) Competitors

CureVac (NASDAQ:CVAC) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.

Which has more risk and volatility, CVAC or GNFT?

CureVac has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in CVAC or GNFT?

17.3% of CureVac shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 4.2% of Genfit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is CVAC or GNFT more profitable?

CureVac has a net margin of 20.72% compared to Genfit's net margin of 0.00%. CureVac's return on equity of 21.98% beat Genfit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	20.72%	21.98%	15.72%
Genfit	N/A	N/A	N/A

Does the MarketBeat Community favor CVAC or GNFT?

Genfit received 43 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 69.70% of users gave Genfit an outperform vote while only 55.32% of users gave CureVac an outperform vote.

Company	Underperform	Outperform
CureVac	Outperform Votes 26 55.32%	Underperform Votes 21 44.68%
Genfit	Outperform Votes 69 69.70%	Underperform Votes 30 30.30%

Which has stronger earnings & valuation, CVAC or GNFT?

Genfit has lower revenue, but higher earnings than CureVac.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$58.18M	12.70	-$281.58M	$0.55	6.00
Genfit	$41.31M	4.61	-$31.27M	N/A	N/A

Does the media prefer CVAC or GNFT?

In the previous week, CureVac had 3 more articles in the media than Genfit. MarketBeat recorded 7 mentions for CureVac and 4 mentions for Genfit. CureVac's average media sentiment score of 0.52 beat Genfit's score of 0.48 indicating that CureVac is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CureVac	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genfit	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate CVAC or GNFT?

CureVac presently has a consensus target price of $10.00, indicating a potential upside of 203.03%. Genfit has a consensus target price of $13.00, indicating a potential upside of 241.66%. Given Genfit's stronger consensus rating and higher possible upside, analysts clearly believe Genfit is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Genfit	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

CureVac beats Genfit on 9 of the 15 factors compared between the two stocks.